Browsing: biologics

This week in the news we were reminded again of body wisdom — the body is resilient and is designed…

Donna Fernandez didn’t know what to expect when she agreed to participate in an immunotherapy clinical trial. “It never occurred…

This week, MedShadow founder Su Robotti and content manager Jonathan Block take a look at the FDA’s reporting system for…

The FDA gave accelerated approval to the biologic Keytruda (pembrolizumab) for patients whose solid cancer tumors have a specific genetic…

Nearly one-third of new drugs approved by the FDA over a recent 10-year period were associated with a postmarket safety…

A new study finds that nearly 1 out of 3 drugs approved by the FDA has a safety issue after…

Scott Gottlieb, President Trump’s nominee to head the FDA, is in most ways a conventional (conservative) choice to head the…

The FDA approved Ocrevus (ocrelizumab) as the first-ever drug to treat primary progressive multiple sclerosis (PPMS), a serious form of…

It is estimated that more than 50 million Americans have arthritis, which is the top cause of disability in the…

The top three categories of pharmaceutical spending in 2016 were biologic anti-inflammatory drugs, diabetes medications and cancer therapies. In its…